WallStreetZenWallStreetZen

NASDAQ: CYTO
Altamira Therapeutics Ltd Earnings & Revenue

OverviewEarnings
DividendOwnership

CYTO earnings and revenue history

Current Revenue
$1.4M
Current Earnings
-$18.9M
Current Profit Margin
-1,394.2%

CYTO Return on Equity

Current Company
-129.3%
Current Industry
3.9%
Current Market
22.1%
CYTO's Return on Equity (-129.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CYTO announces earnings.

CYTO Return on Assets

Current Company
-85%
Current Industry
3.3%
CYTO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CYTO Return on Capital Employed

Current Company
-202.11%
Current Industry
9.5%
CYTO's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CYTO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CYTO$1.35M-$18.37M-$18.89MN/AN/A
DRMA$0.00-$9.67M-$9.61MN/AN/A
TENX$0.00-$11.59M-$11.71MN/AN/A
CFRX$0.00-$59.56M-$59.71MN/AN/A
REVB$0.00-$13.43M-$13.48MN/AN/A
View Top Biotech Stocks

Altamira Therapeutics Earnings & Revenue FAQ

What were CYTO's earnings last quarter?

Altamira Therapeutics (NASDAQ: CYTO) reported Q2 2022 earnings per share (EPS) of N/A, up N/A year over year. Total Altamira Therapeutics earnings for the quarter were N/A. In the same quarter last year, Altamira Therapeutics's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Altamira Therapeutics stock.

What was CYTO's earnings growth in the past year?

As of Q1 2023, Altamira Therapeutics's earnings has grown year over year. Altamira Therapeutics's earnings in the past year totalled -$18.89 million.

What was CYTO's revenue last quarter?

Altamira Therapeutics (NASDAQ: CYTO) reported Q2 2022 revenue of N/A up N/A year over year. In the same quarter last year, Altamira Therapeutics's revenue was N/A.

What was CYTO's revenue growth in the past year?

As of Q1 2023, Altamira Therapeutics's revenue has grown null year over year. Altamira Therapeutics's revenue in the past year totalled $1.35 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.